MP26-13 THE IMPACT OF AIRSEAL ® ON COMPLICATIONS AND PAIN MANAGEMENT DURING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: A SINGLE-TERTIARY CENTER RETROSPECTIVE STUDY

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP26-13 THE IMPACT OF AIRSEAL® ON COMPLICATIONS AND PAIN MANAGEMENT DURING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: A SINGLE-TERTIARY CENTER RETROSPECTIVE STUDY Christian Habib Ayoub, Alexandre Armache, Jose M. El-Asmar, Suhaib Abdulfattah, Nayda Bidikian, Elia Abou Chawareb, Elio Hoyek, and Albert El Hajj Christian Habib AyoubChristian Habib Ayoub More articles by this author , Alexandre ArmacheAlexandre Armache More articles by this author , Jose M. El-AsmarJose M. El-Asmar More articles by this author , Suhaib AbdulfattahSuhaib Abdulfattah More articles by this author , Nayda BidikianNayda Bidikian More articles by this author , Elia Abou ChawarebElia Abou Chawareb More articles by this author , Elio HoyekElio Hoyek More articles by this author , and Albert El HajjAlbert El Hajj More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003254.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: AirSeal® is a valveless insufflation device that allows a stable pneumoperitoneum through continuous smoke evacuation and CO2 recirculation during laparoscopic surgery. We aimed to compare surgical characteristics, post-operative complications, and opioid use between AirSeal® and non-AirSeal® robotic-assisted radical prostatectomy (RARP). METHODS: Data on 395 patients who underwent elective RARP with or without AirSeal® at our institution were retrospectively collected between 2013 and 2022. We compared patient demographics, oncologic, pathologic, and surgical characteristics between AirSeal® and non-AirSeal® cases. We also compared operative time, length of stay, morbidity, and opioid use for pain management between the two groups. Multivariable linear and logistic regression models, controlling for age, extra-prostatic extension, prostate size, and pathological grade on TRUS were developed to control for confounders. RESULTS: The AirSeal® and non-AirSeal® group consisted of 125 and 270 patients respectively. Patients who underwent RARP with AirSeal® were older, more likely to have a clinical grade ≥ 3, and more likely to have extraprostatic extension as compared to patients who did not use AirSeal® (p<0.039). RARP with AirSeal® displayed shorter operative times by 29.2 minutes and length of hospital stay by 0.72 days as compared to non-AirSeal® group (p<0.001). Furthermore, the AirSeal® group also witnessed lower odds of Clavien-Dindo Class >2 complications (OR= 0.06) and opioid use (OR= 0.46) as compared to non-AirSeal® group (p<0.022). CONCLUSIONS: RARP combined with AirSeal® in our center was associated with shorter operative times, shorter length of hospital stays, lower odds of CVD>2 complications, and lower odds of opioid use in comparison to non-AirSeal® RARP. The feasibility and efficacy of combining the AirSeal® system during RARP should be further studied and evaluated by randomized clinical trials. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e358 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christian Habib Ayoub More articles by this author Alexandre Armache More articles by this author Jose M. El-Asmar More articles by this author Suhaib Abdulfattah More articles by this author Nayda Bidikian More articles by this author Elia Abou Chawareb More articles by this author Elio Hoyek More articles by this author Albert El Hajj More articles by this author Expand All Advertisement PDF downloadLoading ...